CytomX Therapeutics (CTMX) Total Current Liabilities (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Total Current Liabilities came in at $34.0 million in Q1 2026, down 32.23% YoY from $50.2 million in Q1 2025, and down 27.01% on a QoQ basis from $46.6 million in Q4 2025.
CytomX Therapeutics (CTMX) Total Current Liabilities (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Total Current Liabilities data on file, last reported at $34.0 million in Q1 2026.
- Quarterly Total Current Liabilities fell 32.23% year-over-year to $34.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.0 million (down 32.23% YoY) and the FY2025 annual result came in at $46.6 million, down 45.65% from the prior year.
- Total Current Liabilities eased to $34.0 million in Q1 2026, from $46.6 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $155.9 million in Q4 2023 to a low of $34.0 million in Q1 2026.
- A 5-year average of $103.4 million and a median of $119.2 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 95.98% — and 2025, when it slumped 72.54%.
- Tracing CTMX's Total Current Liabilities over 5 years: stood at $152.6 million in 2022, then grew by 2.17% to $155.9 million in 2023, then slumped by 44.99% to $85.8 million in 2024, then sank by 45.65% to $46.6 million in 2025, then retreated by 27.01% to $34.0 million in 2026.
- The last three Total Current Liabilities figures came in at $34.0 million (Q1 2026), $46.6 million (Q4 2025), and $41.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 39.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.86 Mn |
| Mar 31, 2026 | 34.02 Mn |
| Dec 31, 2025 | 46.62 Mn |
| Sep 30, 2025 | 41.03 Mn |
| Jun 30, 2025 | 39.22 Mn |
| Mar 31, 2025 | 50.20 Mn |
| Dec 31, 2024 | 85.77 Mn |
| Sep 30, 2024 | 119.23 Mn |
| Jun 30, 2024 | 142.86 Mn |
| Mar 31, 2024 | 144.54 Mn |
| Dec 31, 2023 | 155.91 Mn |
| Sep 30, 2023 | 146.79 Mn |
| Jun 30, 2023 | 141.38 Mn |
| Mar 31, 2023 | 151.26 Mn |
| Dec 31, 2022 | 152.61 Mn |
| Sep 30, 2022 | 123.64 Mn |
| Jun 30, 2022 | 94.64 Mn |
| Mar 31, 2022 | 87.40 Mn |
| Dec 31, 2021 | 77.87 Mn |
| Sep 30, 2021 | 67.53 Mn |